Tag: Cancer: Lung
Most Americans Don’t Know About Lung Cancer Screening: Survey
Intensity-Modulated Radiotherapy Recommended for Locally Advanced Lung Cancer
Patients receiving IMRT and three-dimensional conformal radiotherapy appear to have similar rates of developing secondary cancer
E-Cigarette Use Linked to Lower Use of Lung Cancer Screening
Similar findings seen for those who previously used combustible cigarettes and currently use electronic cigarettes
Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low
Increase in UTD-LCS prevalence seen with age and number of comorbidities; relatively lower levels seen in Southern states
Lung Cancer Screening Increases Earlier-Stage Diagnoses, Improves Survival
Uptake of lung cancer screening was low, but overall and lung cancer-specific survival improved with screening
ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs
ASCO: Osimertinib Improves Progression-Free Survival in EGFR-Mutated Lung Cancer
Significantly longer progression-free survival, but not overall survival, seen for osimertinib in unresectable EGFR-mutation NSCLC
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
Findings seen among patients with resected ALK-positive non-small cell lung cancer
